BCM has created a new technology to repair diseased, injured, or failing organs. The Autologous Regenerative Tissue Replacement (ARTR™) organ repair technology uses a special 5StageAutograft™ procedure to take a biopsy of healthy cells from the patient’s organ. These cells are used to grow many fully functioning mature, healthy cells. These newly grown and mature healthy cells are surgically inserted back into the patient’s organ where they integrate with the other cells and begin to rapidly multiply to regenerate the patient’s organ back to a healthy state.
This procedure’s five stages are defined by the process sequence which includes: Biopsy – Growth - Implant – Integrate - Outburst. All stages are performed upon the same, single patient over a 30 to 45-day period.
BCM has partnered with RTH Network to be the exclusive global distributor of ARTR™ products. RTH Network also administers the ARTR™ organ repair participating Evaluating Physicians and Operating Surgeons.
BCM is currently in clinical trials, addressing ARTR™ skin and liver organ repair. We are seeking interested participants. Participants are compensated and all costs and expenses are covered, plus the procedure includes a two week say at a Resort and Spa. If you are interested or want to learn more, please visit the RTH Network website, and click on the Patient Join link.
BCM will soon commence clinical trials addressing ARTR™ kidney, lungs, and pancreas organ repairs. This same technology and procedure will also be used to address cartilage, muscles, and bones regeneration and repairs in the near future.
For detailed information on this technology and procedure visit the RTH Network at: https://www.righttohealfoundation.com/ and click on the ARTR™ Information link.
New Jersey Laboratory
For many years, Harvard University Research Laboratory, operated by George Church, has been expanding the science of genetic engineering and tissue regenerative processes. One approach used by Professor Church is to harvest the patient’s skin and to transform that skin sample into new stem cells. Thereafter, the process is to transform those new stem cells into organ specific tissue cells. Currently, the Professor estimates 2 years to prepare for human trials and ten years of human trials before for approval. (See the referenced- 60 Minutes Video below or click link)
BCM, a rapidly emerging leader in tissue engineering and developer of the world’s first known, high volume manufacturing facility for the production of regenerative replacement implant products, uses an alternative approach. The BCM approach harvests high quality cells directly from the patient’s diseased or injured organ. The harvested organ cells are utilized in a BCM proprietary process to grow replacement tissues on a surgical procedure-matching replacement scaffolding. This DNA matched regenerative tissue structure is then surgically placed into the patient’s failing or damaged organ.
Utilizing this proprietary autologous tissue creation and replacement approach, BCM has expanded from organ tissue regenerative process to address regenerative, DNA matched, implant products for many soft tissue organs, skin, cartilage, joint meniscus and bone replacement procedures. (See the BCM Business Plan or Contact BCM).